查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
生物標誌物測試服務市場規模,份額和趨勢分析報告：按服務（生物標誌物檢測開發和驗證,流式細胞術）,用戶（研究機構,CROS）,地區細分市場2022-2030預測
市場調查報告書
商品編碼
1147517

生物標誌物測試服務市場規模,份額和趨勢分析報告：按服務（生物標誌物檢測開發和驗證,流式細胞術）,用戶（研究機構,CROS）,地區細分市場2022-2030預測

Biomarker Testing Services Market Size, Share & Trends Analysis Report By Services (Biomarker Assay Development & Validation, Flow Cytometry), By End-user (Research Institutes, CROS), By Region, And Segment Forecasts, 2022 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

生物標誌物檢測服務市場增長及趨勢

根據 Grand View Research, Inc. 的最新報告，到 2030 年，全球生物標誌物檢測服務的市場規模預計將達到 13.994 億美元，預測期內的複合年增長率為 6.9%。藥物研發投資的增加、對用於治療癌症的精準醫療的需求增加、傳染病和慢性病負擔的增加推動了對生物標誌物檢測的需求等是推動市場增長的主要因素。

在過去五年中，臨床試驗一直在持續增加。例如，根據 ClinicalTrials.gov 的數據，2018 年註冊的試驗超過 262,298 項，而截至 2022 年 9 月註冊的試驗超過 399,518 項。由於臨床研究資金的增加，預計未來幾年臨床試驗將有所改善。預計這將增加對藥物發現研究活動的需求，並支持大流行後時期對生物標誌物測試的需求。

FDA 對使用生物標誌物的藥物的批准率逐年上升。例如，2016年，超過26項使用生物標誌物進行醫學檢測的試驗獲得FDA批准，而2019年，FDA批准了36項使用生物標誌物進行醫學檢測的試驗。藥物批准現在需要與生物標誌物相關的數據，因為臨床試驗提供了有關藥物如何在體內發揮作用的信息，並可以加快藥物批准過程。因此，預計在預測期內對生物標誌物測試的需求將會增加。

各種生物製藥公司正致力於通過生物標誌物檢測來提高癌症患者的診斷率。例如，2021 年 4 月，生物製藥公司 Amgen 啟動了“生物標誌物輔助計劃”。該計劃將對轉移性（IV 期）非小細胞肺癌 (NSCLC) 患者進行生物標誌物測試，以確定是否存在可能對靶向治療有用的致癌基因生物標誌物。市場參與者的這些努力可能會支持市場的增長。

根據 IQVIA 的腫瘤學趨勢報告，癌症臨床試驗在過去十年中持續增加。例如，2011年有1242個癌症臨床試驗註冊，到2021年，將有2335個癌症臨床試驗註冊。由於患病率的增加，預計針對癌症的臨床試驗數量將進一步增加。為癌症設計的靶向治療越來越需要使用生物標誌物來測試研究中的藥物療效。預計未來幾年癌症研究的增加將增加對用於癌症檢測的生物標誌物的需求，從而支持大流行後時期的市場。

生物標誌物檢測服務市場報告要點

按服務劃分的生物標誌物分析開發和驗證部分預計在 2021 年將佔最大份額，達到 59.8%。對診斷疾病的伴隨診斷不斷增長的需求預計將支持對生物標誌物分析開發和驗證服務的需求

隨著製藥和生物技術公司增加研發投資，最終用戶將在 2021 年佔據 44.0% 的最大份額。

到 2021 年，北美將佔 46.2% 的最大份額，擁有技術先進的研究基礎設施和公共機構不斷增加的研究投資，支持該地區的市場增長。

內容

第 1 章調查方法及範圍

  • 市場細分和範圍
    • 服務
    • 最終用戶
    • 區域範圍
  • 調查方法
  • 資訊採購
    • 購買的數據庫
    • GVR 內部數據庫
    • 次要資訊
    • 初步調查
    • 初步調查的內容
  • 資訊或數據分析
    • 數據分析模型
  • 市場製定和驗證
  • 模型詳細資訊
    • 商品流分析（模型 1）
      • 方法 1：商品流方法
    • 批量價格分析（模型 2）
      • 方法 2：體積分析
  • 二級資訊列表
  • 主要資訊列表
  • 目的

第 2 章執行摘要

  • 市場展望

第 3 章生物標誌物檢測服務市場變量、趨勢和範圍

  • 市場系列展望
    • 母公司的市場前景
    • 相關/子公司市場前景
  • 描繪滲透率和增長前景
  • 市場動態
    • 市場促進因素分析
      • 對用於癌症檢測的生物標誌物測試的需求不斷增加
      • 增加研發活動
      • 慢性病和傳染病負擔的增加支持對生物標誌物檢測的需求
    • 市場抑制因素分析
      • 生物標誌物開發的資本投資大且時間長
  • 生物標誌物檢測服務市場分析工具
    • 行業分析 - 波特五力
    • PESTEL 分析
    • 對主要交易和戰略聯盟的分析
      • 併購
      • 分機
      • 合同和合作
      • 產品和服務發布
  • COVID-19 的影響和改革戰略

第 4 章生物標誌物檢測服務市場：產品估計和趨勢分析

  • 定義和範圍
  • 2021 年和 2030 年生物標誌物檢測服務的市場份額
    • 生物標誌物檢測的開發和驗證
    • 流式細胞儀
    • 其他

第 5 章生物標誌物檢測服務市場：最終用戶估計和趨勢分析

  • 定義和範圍
  • 2021 年和 2030 年生物標誌物檢測服務的市場份額
    • 製藥和生物技術公司
    • 調查
    • 交叉

第 6 章生物標誌物檢測服務市場：區域估計和趨勢分析

  • 2021 年和 2030 年區域市場份額分析
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 意大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 瑞士
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 韓國
    • 泰國
    • 馬來西亞
    • 印度尼西亞
    • 台灣
    • 新加坡
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞；
  • 多邊環境協定
    • 南非
    • 沙特阿拉伯
    • 阿拉伯聯合酋長國
    • 以色列

第 7 章競爭分析

  • 主要市場進入者的近期發展和影響分析
  • 公司/競爭對手分類（主要創新者、市場領導者、初創企業）
  • 參與者分類
  • 供應商情況
    • 主要服務提供商名單
    • 市場差異化因素
    • 生物標誌物檢測服務市場份額分析

第 8 章競爭格局

  • 公司簡介
    • Bio Agilytix Labs
      • 公司簡介
      • 服務基準
      • 戰略舉措
    • Eurofins Scientific
      • 公司簡介
      • 財務業績
      • 服務基準
      • 戰略舉措
    • SGS SA
      • 公司簡介
      • 財務業績
      • 服務基準
      • 戰略舉措
    • Charles River Laboratories
      • 公司簡介
      • 財務業績
      • 服務基準
      • 戰略舉措
    • Laboratory Corporation of America Holding
      • 公司簡介
      • 財務業績
      • 服務基準
      • 戰略舉措
    • Thermo Fisher Scientific, Inc. (PPD, Inc.)
      • 公司簡介
      • 財務業績
      • 服務基準
      • 戰略舉措
    • ICON Plc
      • 公司簡介
      • 財務業績
      • 服務基準
      • 戰略舉措
    • IQVIA, Inc.
      • 公司簡介
      • 財務業績
      • 服務基準
      • 戰略舉措
    • Syneos Health
      • 公司簡介
      • 財務業績
      • 服務基準
      • 戰略舉措
    • Intertek Group Plc
      • 公司簡介
      • 財務業績
      • 服務基準
      • 戰略舉措
Product Code: GVR-4-68039-986-1

Biomarker Testing Services Market Growth & Trends:

The global biomarker testing services market size is expected to reach USD 1,399.4 million by 2030, registering a CAGR of 6.9% during the forecast period, according to a new report by Grand View Research, Inc. Growing investment in pharmaceutical R&D, increasing demand for the precision medicine used for cancer treatment, and growing burden of the infectious and chronic diseases facilitating the demand for the biomarker testing are some of the major factors driving the market's growth.

There has been a consistent rise in clinical trials during the last 5 years. For instance, according to ClinicalTrials.gov, more than 262,298 trials were registered in 2018, whereas as of September 2022, above 399,518 trials were registered. Clinical trials are expected to improve in the coming years owing to the increase in funding for clinical research. This is expected to boost demand for medicine discovery research activities and thus support demand for biomarker testing in the post-pandemic period.

The FDA approval rate for medicines through the use of biomarkers has improved, over the years. For instance, in 2016, more than 26 trials were approved by the FDA that used biomarkers for medicine testing, whereas, in 2019, 36 trials were approved by the FDA that used biomarkers for medical testing. Clinical trials now require biomarker-related data for medicine approvals, as it provides information about the action of medicine in the body and thus speeds up the medicine approval process. This is expected to improve demand for biomarker testing during the forecast period.

Various biopharmaceutical companies are taking initiatives to improve the diagnosis rate of the cancer patient through biomarker testing. For instance, in April 2021, a biopharmaceutical company, Amgen launched the Biomarker Assist Program. As per this program, patients with metastatic (stage IV) non-small cell lung cancer (NSCLC) were provided biomarker testing, to check the presence of oncogene biomarkers, which help in targeted therapies. Such initiatives by the market players are likely to support the market's growth.

According to the IQVIA, report on oncology trends, clinical trials for cancer have been increasing for the last 10 years. For instance, in 2011, 1,242 trials were registered for cancer, and as of 2021, 2,335 trials were registered for cancer. The number of clinical trials intended for cancer is expected to rise even further owing to the growing prevalence of the disease. There is an increasing demand for targeted therapies designed for cancer that use biomarkers for testing the efficacy of the drug in the research. Increased cancer research in the coming years is expected to boost demand for the biomarkers designed for cancer testing and thus support the market in the post-pandemic period.

Biomarker Testing Services Market Report Highlights:

  • The biomarker assay development & validation segment by service was expected to hold the largest share of 59.8% in 2021. Growing demand for companion diagnostics in the diagnosis of diseases is expected to support demand for the biomarker assay development & validation service
  • Based on end-user, the pharmaceutical and biotechnology companies accounted for the largest share of 44.0% in 2021, owing to the rising investment in R&D by these companies
  • North America held the largest share of 46.2% in 2021, The technologically advanced infrastructure for research and the increase in research investment by public organizations are supporting the regional market growth

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Services
    • 1.1.2. End-user
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
      • 1.6.1.1. Approach 1: Commodity flow approach
    • 1.6.2. Volume price analysis (Model 2)
      • 1.6.2.1. Approach 2: Volume price analysis
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives
    • 1.9.1. Objective 1
    • 1.9.2. Objective 2

Chapter 2. Executive Summary

  • 2.1. Market Outlook

Chapter 3. Biomarker Testing Services Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
      • 3.3.1.1. Increasing demand for biomarker testing for cancer detection
      • 3.3.1.2. Increasing R&D activities
      • 3.3.1.3. Growing burden of chronic and infectious diseases supporting demand for biomarker testing
    • 3.3.2. Market restraint analysis
      • 3.3.2.1. High capital investments and lengthy timelines for biomarker development
  • 3.4. Biomarker Testing Services Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
    • 3.4.2. PESTEL Analysis
    • 3.4.3. Major Deals & Strategic Alliances Analysis
      • 3.4.3.1. Mergers and Acquisition
      • 3.4.3.2. Expansions
      • 3.4.3.3. Agreements and Collaborations
      • 3.4.3.4. Product and Service Launches
  • 3.5. Covid-19 Impact and Reformation Strategy

Chapter 4. Biomarker Testing Services Market: Product Estimates & Trend Analysis

  • 4.1. Definitions and Scope
  • 4.2. Biomarker Testing Services Market Share, 2021 & 2030
    • 4.2.1. Biomarker Assay Development & Validation
      • 4.2.1.1. Biomarker assay development & validation market estimates and forecast 2018 to 2030 (USD Billion)
    • 4.2.2. Flow cytometry
      • 4.2.2.1. Flow cytometry market estimates and forecast 2018 to 2030 (USD Billion)
    • 4.2.3. Others
      • 4.2.3.1. Others market estimates and forecast 2018 to 2030 (USD Billion)

Chapter 5. Biomarker Testing Services Market: End-user Estimates & Trend Analysis

  • 5.1. Definitions and Scope
  • 5.2. Biomarker Testing Services Market Share, 2021 & 2030
    • 5.2.1. Pharmaceutical and biotechnology companies
      • 5.2.1.1. Pharmaceutical and biotechnology companies market estimates and forecast 2018 to 2030 (USD Billion)
    • 5.2.2. Research Institutes
      • 5.2.2.1. Research Institutes market estimates and forecast 2018 to 2030 (USD Billion)
    • 5.2.3. CROS
      • 5.2.3.1. CROS market estimates and forecast 2018 to 2030 (USD Billion)

Chapter 6. Biomarker Testing Services Market: Regional Estimates & Trend Analysis

  • 6.1. Regional market share analysis, 2021& 2030
  • 6.2. North America
    • 6.2.1. U.S.
      • 6.2.1.1. U.S. Market estimates and forecast, 2018 - 2030
    • 6.2.2. Canada
      • 6.2.2.1. Canada Market estimates and forecast, 2018 - 2030
  • 6.3. Europe
    • 6.3.1. U.K.
      • 6.3.1.1. U.K. Market estimates and forecast, 2018 - 2030
    • 6.3.2. Germany
      • 6.3.2.1. Germany Market estimates and forecast, 2018 - 2030
    • 6.3.3. France
      • 6.3.3.1. France Market estimates and forecast, 2018 - 2030
    • 6.3.4. Italy
      • 6.3.4.1. Italy Market estimates and forecast, 2018 - 2030
    • 6.3.5. Spain
      • 6.3.5.1. Spain Market estimates and forecast, 2018 - 2030
    • 6.3.6. Netherlands
      • 6.3.6.1. Netherlands Market estimates and forecast, 2018 - 2030
    • 6.3.7. Sweden
      • 6.3.7.1. Sweden Market estimates and forecast, 2018 - 2030
    • 6.3.8. Switzerland
      • 6.3.8.1. Switzerland Market estimates and forecast, 2018 - 2030
  • 6.4. Asia Pacific
    • 6.4.1. Japan
      • 6.4.1.1. Japan Market estimates and forecast, 2018 - 2030
    • 6.4.2. China
      • 6.4.2.1. China Market estimates and forecast, 2018 - 2030
    • 6.4.3. India
      • 6.4.3.1. India Market estimates and forecast, 2018 - 2030
    • 6.4.4. Australia
      • 6.4.4.1. Australia Market estimates and forecast, 2018 - 2030
    • 6.4.5. South Korea
      • 6.4.5.1. South Korea Market estimates and forecast, 2018 - 2030
    • 6.4.6. Thailand
      • 6.4.6.1. Thailand Market estimates and forecast, 2018 - 2030
    • 6.4.7. Malaysia
      • 6.4.7.1. Malaysia Market estimates and forecast, 2018 - 2030
    • 6.4.8. Indonesia
      • 6.4.8.1. New Zealand Market estimates and forecast, 2018 - 2030
    • 6.4.9. Taiwan
      • 6.4.9.1. Philippines Market estimates and forecast, 2018 - 2030
    • 6.4.10. Singapore
      • 6.4.10.1. Singapore Market estimates and forecast, 2018 - 2030
  • 6.5. Latin America
    • 6.5.1. Brazil
      • 6.5.1.1. Brazil Market estimates and forecast, 2018 - 2030
    • 6.5.2. Mexico
      • 6.5.2.1. Mexico Market estimates and forecast, 2018 - 2030
    • 6.5.3. Argentina
      • 6.5.3.1. Argentina Market estimates and forecast, 2018 - 2030
    • 6.5.4. Colombia;
      • 6.5.4.1. Colombia Market estimates and forecast, 2018 - 2030
  • 6.6. MEA
    • 6.6.1. South Africa
      • 6.6.1.1. South Africa Market estimates and forecast, 2018 - 2030
    • 6.6.2. Saudi Arabia
      • 6.6.2.1. Saudi Arabia Market estimates and forecast, 2018 - 2030
    • 6.6.3. UAE
      • 6.6.3.1. UAE Market estimates and forecast, 2018 - 2030
    • 6.6.4. Israel
      • 6.6.4.1. Israel Market estimates and forecast, 2018 - 2030

Chapter 7. Competitive Analysis

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participant
  • 7.2. Company/Competition Categorization (Key Innovators, Market Leaders, Emerging Players)
  • 7.3. Participant Categorization
  • 7.4. Vendor Landscape
    • 7.4.1. List of Key Service Providers
    • 7.4.2. Market Differentiators
    • 7.4.3. Biomarker Testing Services Market Share Analysis

Chapter 8. Competitive Landscape

  • 8.1. Company Profiles
    • 8.1.1. Bio Agilytix Labs
      • 8.1.1.1. Company overview
      • 8.1.1.2. Service Benchmarking
      • 8.1.1.3. Strategic initiatives
    • 8.1.2. Eurofins Scientific
      • 8.1.2.1. Company overview
      • 8.1.2.2. Financial performance
      • 8.1.2.3. Service Benchmarking
      • 8.1.2.4. Strategic initiatives
    • 8.1.3. SGS SA
      • 8.1.3.1. Company overview
      • 8.1.3.2. Financial performance
      • 8.1.3.3. Service Benchmarking
      • 8.1.3.4. Strategic initiatives
    • 8.1.4. Charles River Laboratories
      • 8.1.4.1. Company overview
      • 8.1.4.2. Financial performance
      • 8.1.4.3. Service Benchmarking
      • 8.1.4.4. Strategic initiatives
    • 8.1.5. Laboratory Corporation of America Holding
      • 8.1.5.1. Company overview
      • 8.1.5.2. Financial performance
      • 8.1.5.3. Service Benchmarking
      • 8.1.5.4. Strategic initiatives
    • 8.1.6. Thermo Fisher Scientific, Inc. (PPD, Inc.)
      • 8.1.6.1. Company overview
      • 8.1.6.2. Financial performance
      • 8.1.6.3. Service Benchmarking
      • 8.1.6.4. Strategic initiatives
    • 8.1.7. ICON Plc
      • 8.1.7.1. Company overview
      • 8.1.7.2. Financial performance
      • 8.1.7.3. Service Benchmarking
      • 8.1.7.4. Strategic initiatives
    • 8.1.8. IQVIA, Inc.
      • 8.1.8.1. Company overview
      • 8.1.8.2. Financial performance
      • 8.1.8.3. Service Benchmarking
      • 8.1.8.4. Strategic initiatives
    • 8.1.9. Syneos Health
      • 8.1.9.1. Company overview
      • 8.1.9.2. Financial performance
      • 8.1.9.3. Service Benchmarking
      • 8.1.9.4. Strategic initiatives
    • 8.1.10. Intertek Group Plc
      • 8.1.10.1. Company overview
      • 8.1.10.2. Financial performance
      • 8.1.10.3. Service Benchmarking
      • 8.1.10.4. Strategic initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of Abbreviations

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value - chain - based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Commodity flow analysis
  • Fig. 9 Volume Price Analysis
  • Fig. 10 Biomarker Testing Services market snapshot (2021)
  • Fig. 11 Biomarker Testing Services market segmentation
  • Fig. 12 Market driver relevance analysis (Current & future impact)
  • Fig. 13 Market restraint relevance analysis (Current & future impact)
  • Fig. 14 Penetration & growth prospect mapping
  • Fig. 15 Porter's five forces analysis
  • Fig. 16 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 17 Biomarker Testing Services market service outlook: Segment dashboard
  • Fig. 18 Biomarker Testing Services market: Service movement analysis
  • Fig. 19 Biomarker Assay Development & Validation market (USD Million)
  • Fig. 20 Flow cytometry market (USD Million)
  • Fig. 21 Others market (USD Million)
  • Fig. 22 Biomarker Testing Services market End - user outlook: Segment dashboard
  • Fig. 23 Biomarker Testing Services market: End - user movement analysis
  • Fig. 24 Pharmaceutical and biotechnology companies market (USD Million)
  • Fig. 25 Research Institutes market (USD Million)
  • Fig. 26 CROs market (USD Million)
  • Fig. 27 Regional market: Key takeaways
  • Fig. 28 Regional outlook, 2021 & 2030
  • Fig. 29 North America market, 2018 - 2030 (USD Million)
  • Fig. 30 U.S. market, 2018 - 2030 (USD Million)
  • Fig. 31 Canada Market, 2018 - 2030 (USD Million)
  • Fig. 32 Europe Market, 2018 - 2030 (USD Million)
  • Fig. 33 U.K Market, 2018 - 2030 (USD Million)
  • Fig. 34 Germany Market, 2018 - 2030 (USD Million)
  • Fig. 35 France Market, 2018 - 2030 (USD Million)
  • Fig. 36 Italy Market, 2018 - 2030 (USD Million)
  • Fig. 37 Spain Market, 2018 - 2030 (USD Million)
  • Fig. 38 Netherlands Market, 2018 - 2030 (USD Million)
  • Fig. 39 Switzerland Market, 2018 - 2030 (USD Million)
  • Fig. 40 Sweden Market, By Service, 2018 - 2030 (USD Million)
  • Fig. 41 Asia Pacific market, 2018 - 2030 (USD Million)
  • Fig. 42 China market, 2018 - 2030 (USD Million)
  • Fig. 43 India market, 2018 - 2030 (USD Million)
  • Fig. 44 Japan market, 2018 - 2030 (USD Million)
  • Fig. 45 Australia market, 2018 - 2030 (USD Million)
  • Fig. 46 Malaysia market, 2018 - 2030 (USD Million)
  • Fig. 47 Indonesia market, 2018 - 2030 (USD Million)
  • Fig. 48 Taiwan market, 2018 - 2030 (USD Million)
  • Fig. 49 Thailand market, 2018 - 2030 (USD Million)
  • Fig. 50 Singapore market, 2018 - 2030 (USD Million)
  • Fig. 51 South Korea market, 2018 - 2030 (USD Million)
  • Fig. 52 Latin America market, 2018 - 2030 (USD Million)
  • Fig. 53 Brazil market, 2018 - 2030 (USD Million)
  • Fig. 54 Mexico market, 2018 - 2030 (USD Million)
  • Fig. 55 Argentina market, 2018 - 2030 (USD Million)
  • Fig. 56 Colombia market, 2018 - 2030 (USD Million)
  • Fig. 57 MEA market, 2018 - 2030 (USD Million)
  • Fig. 58 South Africa market, 2018 - 2030 (USD Million)
  • Fig. 59 Saudi Arabia market, 2018 - 2030 (USD Million)
  • Fig. 60 Israel market, 2018 - 2030 (USD Million)
  • Fig. 61 UAE market, 2018 - 2030 (USD Million)